Bristol Myers Squibb vs Teva Pharmaceutical Industries
Bristol Myers Squibb (BMY) and Teva Pharmaceutical Industries (TEVA) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $120B
- Last close
- $58.80
- 12 months
- +28.0%
- Market value
- $45.8B
- Last close
- $39.23
- 12 months
- +61.6%
At a glance
- The biggest part of Bristol Myers Squibb's revenue is Growth Portfolio (55%); at Teva Pharmaceutical Industries it is Sale of Goods (85%).
- By market value, Bristol Myers Squibb ($120.2B) is about 2.6 times Teva Pharmaceutical Industries ($45.8B).
- Over the last 12 months Bristol Myers Squibb's share price moved +28.0% and Teva Pharmaceutical Industries's +61.6%; against the S&P 500 that is +22.3 points and +55.9 points.
- In their last fiscal years Bristol Myers Squibb kept 14.6% of revenue as net income and Teva Pharmaceutical Industries 8.2%.
- In the last 90 days insiders reported 0 open-market purchases at Bristol Myers Squibb and 0 at Teva Pharmaceutical Industries; members of Congress disclosed 0 trades in Bristol Myers Squibb and 0 in Teva Pharmaceutical Industries.
- Next results: Bristol Myers Squibb Feb 3, 2027, Teva Pharmaceutical Industries not announced.
How each one makes money: Bristol Myers Squibb revenue · Teva Pharmaceutical Industries revenue
Share prices on one chart
Bristol Myers Squibb and Teva Pharmaceutical Industries, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Bristol Myers Squibb BMYNYSE · Pharmaceuticals | Teva Pharmaceutical Industries TEVANYSE · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $120B | $45.8B |
| Revenue, last fiscal year | $48.2B | $17.3B |
| Net income, last fiscal year | $7.05B | $1.41B |
| Net marginNet income as a share of revenue | 14.6% | 8.2% |
| Free cash flow | $12.8B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Bristol Myers Squibb against
Common questions
How is Bristol Myers Squibb different from Teva Pharmaceutical Industries?
Bristol Myers Squibb (BMY) is in Pharmaceuticals on NYSE, with $48.2B of revenue in its last fiscal year and a net margin of 14.6%. Teva Pharmaceutical Industries (TEVA) is in Pharmaceutical Preparations on NYSE, with $17.3B of revenue in its last fiscal year and a net margin of 8.2%. The biggest part of Bristol Myers Squibb's revenue is Growth Portfolio (55%); at Teva Pharmaceutical Industries it is Sale of Goods (85%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Bristol Myers Squibb and Teva Pharmaceutical Industries compare in size?
Bristol Myers Squibb has the larger market value: Bristol Myers Squibb $120B and Teva Pharmaceutical Industries $45.8B, at the last close.
Whose share price rose more over the last 12 months, BMY or TEVA?
Over the last 12 months Bristol Myers Squibb moved +28.0% and Teva Pharmaceutical Industries +61.6%. Past price moves say nothing about the future.
Which has had more insider buying, Bristol Myers Squibb or Teva Pharmaceutical Industries?
Since 2006, Bristol Myers Squibb insiders reported 47 open-market purchases against 6 for Teva Pharmaceutical Industries. These are counts of what was filed, not a view on either stock.
Do members of Congress trade BMY or TEVA?
In the last 12 months, members of Congress disclosed 8 trades in Bristol Myers Squibb (BMY) and 0 in Teva Pharmaceutical Industries (TEVA).
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Bristol Myers Squibb pageTeva Pharmaceutical Industries pageRare insider trades this weekAll comparisons
https://oqro.io/compare/bmy-vs-teva







